Important Information for Veterinarians About TANOVEA-CA1
Designed to target and kill lymphoma cells 1, 2
- Accumulates primarily in lymphoid cells
- Inhibits the proliferation of lymphocytes and lymphoma cell lines by inhibiting DNA synthesis
Easy to administer
- One dose every three weeks
- Only five doses for full treatment
- Simple, 30-minute intravenous infusion of 1 mg/kg
- Stepwise dose reductions or dose delays can help manage adverse reactions
Reasonable expectation of efficacy 3
- 77% overall response rate in clinical studies in 22 dogs receiving TANOVEA-CA1 once every three weeks
- 134 day overall median progression-free survival time in responding dogs
- Can be used in dogs with naive and relapsed/refractory lymphoma
Generally well-tolerated in clinical studies 3
- The majority of adverse reactions were Veterinary Cooperative Oncology Group (VCOG)4 grade 1 or 2
- Common adverse reactions included neutropenia, diarrhea, anorexia, weight loss, lethargy, and skin problems
- Less frequent, but more severe adverse reactions have occurred – see prescribing information for further details
- Most adverse reactions resolved spontaneously, with supportive treatment, dose modifications, or dose delays
States Where TANOVEA-CA1 is Currently Available for Purchase
TANOVEA-CA1 is available in all 50 US states.
TANOVEA-CA1 was found to inhibit lymphoma cell proliferation in vivo.
Uptake of the 18F-fluorothymidine tracer via positron emission tomography/computed tomography (PET/CT) following TANOVEA-CA1 treatment.5, 6
Figure B shows the same dog nine weeks following TANOVEA-CA1 treatment, with markedly reduced tracer uptake in the lymph nodes, which correlated with a complete response in this dog.
TANOVEA-CA1 mechanism of action
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-475.
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.
Important Safety Information: TANOVEA-CA1 is indicated for the treatment of lymphoma in dogs. In clinical trials, the most frequently reported adverse reactions included decreased white blood cell count, diarrhea, vomiting, decreased or loss of appetite, weight loss, decreased activity level, and skin problems. Serious and sometimes fatal respiratory complications, including pulmonary fibrosis have occurred in dogs treated with TANOVEA-CA1. Do not use in West Highland White Terriers and use with caution in other terrier breeds. Owners should take extra care when handling and cleaning up after their dog for five days after treatment. Please see the package insert for full prescribing information, warnings and precautions.
As with other cytotoxic drugs commonly administered via intravenous infusion, extra caution is warranted to avoid extravasation. Limited information exists on the vesicant/irritant properties of TANOVEA-CA1. In the event of extravasation, please contact VetDC at 1-877-468-3832 for additional guidance.
REFERENCES 1. Reiser H, Wang J, Chong L, et al. GS-9219—A novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin’s lymphoma. Clin Cancer Res 2008;14:2824–2832. 2. Kramata P, Downey KM, Paborsky LR. Incorportation and excision of 9-(2-phosphonylmethoxyethyl)guanine (PMEG) by DNA polymerase delta and epsilon in vitro. J Biol Chem 1998;273:21966–21971. 3. TANOVEA-CA1 [package insert]. VetDC Inc., Dec 2016. Data on file, VetDC Inc., Fort Collins, CO. 4. Veterinary Cooperative Oncology Group – common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biologic antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 20 Jul 2011, DOI: 10.1111/j.1476-5829.2011.00283.x. 5. Lawrence J, Vanderhoek M, Barbee D, et al. Use of 3’-deoxy-3’-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin’s lymphoma. Vet Radiol Ultrasound 2009;50:660–668. 6. Vail DM, Thamm DH, Reiser H, Ray AS, Wolfgang GHI, Watkins WJ, Babusis D, Henne IN, Hawkins MJ, Kurzman ID, Jeraj R, Vanderhoek M, Plaza S. Assessment of GS-9219 in a pet dog model of non-Hodgkin’s lymphoma. Clin Cancer Res 2009 May 15;15(10):3503-10.